|
CEP63 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.26119999952235E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.95144999999286E-05 |
| Normal-vs-Stage2 |
9.415800E-04 |
| Normal-vs-Stage3 |
1.28389999964895E-07 |
| Normal-vs-Stage4 |
1.63337999999902E-05 |
| Stage1-vs-Stage2 |
9.479600E-01 |
| Stage1-vs-Stage3 |
6.362100E-02 |
| Stage1-vs-Stage4 |
3.184200E-01 |
| Stage2-vs-Stage3 |
2.353200E-01 |
| Stage2-vs-Stage4 |
5.218000E-01 |
| Stage3-vs-Stage4 |
5.816400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.13740000038132E-07 |
| Normal-vs-AfricanAmerican |
6.637600E-03 |
| Normal-vs-Asian |
5.824100E-03 |
| Caucasian-vs-AfricanAmerican |
6.483400E-01 |
| Caucasian-vs-Asian |
2.067000E-01 |
| AfricanAmerican-vs-Asian |
6.718800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.28650000050546E-07 |
| Normal-vs-Female |
2.31370000003395E-06 |
| Male-vs-Female |
2.813800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.39009999999373E-05 |
| Normal-vs-Age(41-60Yrs) |
2.01599999999358E-05 |
| Normal-vs-Age(61-80Yrs) |
3.0481000001803E-07 |
| Normal-vs-Age(81-100Yrs) |
3.303100E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.971200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.315600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.601200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.197000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.571600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.137800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.251360E-01 |
| Classical-VS-Follicular |
7.642400E-02 |
| Classical-VS-Other |
1.122200E-01 |
| Classical-VS-Normal |
3.65860000000051E-05 |
| Tall-VS-Follicular |
7.481200E-01 |
| Tall-VS-Other |
4.090400E-01 |
| Tall-VS-Normal |
5.67089999999881E-05 |
| Follicular-VS-Other |
4.092000E-01 |
| Follicular-VS-Normal |
1.99528000000004E-05 |
| Other-VS-Normal |
2.744100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.37970000005472E-06 |
| Normal-vs-N1 |
1.14829999997568E-06 |
| N0-vs-N1 |
1.847820E-01 |
|
|
